BPG is committed to discovery and dissemination of knowledge
Retrospective Cohort Study
Copyright: ©Author(s) 2026.
World J Clin Oncol. Nov 24, 2026; 17(11): 125117
Published online Nov 24, 2026. doi: 10.5306/wjco.125117
Table 1 Baseline characteristics by disease-free survival event status, n (%)
Characteristic
All patients (n = 440)
No DFS event (n = 281)
DFS event (n = 159)
P value
Age, years64.00 (56.00, 70.00)64.00 (58.00, 70.00)65.00 (55.50, 72.00)0.398
Sex
    Male253 (57.5)174 (61.9)79 (49.7)0.017
    Female187 (42.5)107 (38.1)80 (50.3)
Body mass index22.79 (20.66, 24.77)22.59 (20.59, 24.67)23.03 (20.80, 24.90)0.262
ASA classification
    I-II367 (83.4)246 (87.5)121 (76.1)0.003
    III or higher73 (16.6)35 (12.5)38 (23.9)
Tumor site
    Right-sided colon111 (25.2)66 (23.5)45 (28.3)0.465
    Left-sided colon112 (25.5)71 (25.3)41 (25.8)
    Rectum217 (49.3)144 (51.2)73 (45.9)
Preoperative bowel obstruction
    No416 (94.5)271 (96.4)145 (91.2)0.035
    Yes24 (5.5)10 (3.6)14 (8.8)
Preoperative CEA, ng/mL3.84 (2.08, 9.93)3.46 (2.00, 8.33)4.42 (2.25, 11.34)0.065
Preoperative CA19-9, U/mL6.53 (2.50, 16.66)5.63 (2.44, 13.37)8.72 (2.79, 28.22)0.009
Preoperative albumin, g/L38.00 (35.00, 40.40)37.90 (34.90, 40.20)38.30 (35.25, 40.70)0.428
Neutrophil-to-lymphocyte ratio2.04 (1.55, 2.92)2.02 (1.51, 2.86)2.07 (1.59, 3.08)0.255
pT4 subtype
    pT4a329 (74.8)215 (76.5)114 (71.7)0.316
    pT4b111 (25.2)66 (23.5)45 (28.3)
pN stage
    pN0155 (35.2)120 (42.7)35 (22.0)< 0.001
    pN1179 (40.7)106 (37.7)73 (45.9)
    pN2106 (24.1)55 (19.6)51 (32.1)
Tumor size
    ≤ 5 cm274 (62.3)172 (61.2)102 (64.2)0.611
    > 5 cm166 (37.7)109 (38.8)57 (35.8)
Histological type
    Conventional adenocarcinoma405 (92.0)263 (93.6)142 (89.3)0.244
    Mucinous adenocarcinoma17 (3.9)8 (2.8)9 (5.7)
    Signet-ring cell carcinoma or other special type18 (4.1)10 (3.6)8 (5.0)
Differentiation grade
    Moderate/well differentiation365 (83.0)244 (86.8)121 (76.1)0.006
    Poor differentiation75 (17.0)37 (13.2)38 (23.9)
Lymphovascular invasion
    Negative278 (63.2)191 (68.0)87 (54.7)0.008
    Positive162 (36.8)90 (32.0)72 (45.3)
Perineural invasion
    Negative287 (65.2)192 (68.3)95 (59.7)0.087
    Positive153 (34.8)89 (31.7)64 (40.3)
Table 2 Final Cox model after least absolute shrinkage and selection operator selection
Term or comparison
Coefficient
SE
HR (95%CI)
P value
ln(CA19-9 + 1)0.1220320.0500611.130 (1.024-1.246)0.015
Female vs male0.3092780.1625031.362 (0.991-1.873)0.057
ASA III or higher vs ASA I-II0.4726200.1953951.604 (1.094-2.353)0.016
Preoperative bowel obstruction: Yes vs no0.4233220.3016511.527 (0.845-2.758)0.161
Poor vs moderate/well differentiation0.3868380.1913371.472 (1.012-2.142)0.043
Lymphovascular invasion: Positive vs negative0.2498500.1704851.284 (0.919-1.793)0.143
pN1 vs pN00.5659600.2116121.761 (1.163-2.666)0.007
pN2 vs pN00.6964160.2289782.007 (1.281-3.143)0.002
Table 3 Discrimination of the proposed model and TNM-only comparator
Model
Measure
Estimate
95%CI
Proposed modelHarrell C-index0.6700.628-0.711
Conditional bootstrap optimism-corrected C-index0.652Not estimated
Time-dependent AUC at 36 months0.7040.650-0.756
Time-dependent AUC at 60 months0.7170.644-0.780
TNM-only comparatorHarrell C-index0.6090.567-0.650
Conditional bootstrap optimism-corrected C-index0.598Not estimated
Time-dependent AUC at 36 months0.6210.564-0.677
Time-dependent AUC at 60 months0.5420.458-0.626


Write to the Help Desk